المؤلفون: Le Tourneau, C., Piha-Paul, S., Prenen, H., Delafontaine, B., Pinato, D., Santoro, A., Kristeleit, R., Spencer, K., Gangadhar, T., Burris, H., Kotecki, N., Basu, B., Graham, Donna, Di Giacomo, A. M., Sahebjam, S., Di Nicola, M., Gomez-Roca, C., Tomasini, P., Ascierto, P., Curigliano, G., Karasic, T., Geschwindt, R., Daniel, J., Van Cutsem, E.

المساهمون: Institut Curie, Paris, France

Relation: https://dx.doi.org/10.1136/jitc-2022-SITC2022.0774; Le Tourneau C, Piha-Paul S, Prenen H, Delafontaine B, Pinato D, Santoro A, et al. A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule Pd-L1 Inhibitor, Incb086550, in Patients with Select Advanced Tumors. Journal for immunotherapy of cancer. 2022 Nov;10:A805-A. PubMed PMID: WOS:000919423400730.; http://hdl.handle.net/10541/626278; Journal for Immunotherapy of Cancer

الاتاحة: http://hdl.handle.net/10541/626278
https://doi.org/10.1136/jitc-2022-SITC2022.0774

المؤلفون: Van Cutsem, E., Prenen, H., Delafontaine, B., Spencer, K., Mitchell, T., Burris, H., Kotecki, N., Kristeleit, R., Pinato, D., Sahebjam, S., Graham, Donna, Karasic, T., Daniel, J., O'Hayer, K., Geschwindt, R., Piha-Paul, S.

المساهمون: University of Leuven, Leuven, Belgium

Relation: https://dx.doi.org/10.1136/jitc-2021-SITC2021.529; Cutsem EV, Prenen H, Delafontaine B, Spencer K, Mitchell T, Burris H, et al. 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. Vol. 9, Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A559–60.; http://hdl.handle.net/10541/625247; Journal for Immunotherapy of Cancer

الاتاحة: http://hdl.handle.net/10541/625247
https://doi.org/10.1136/jitc-2021-SITC2021.529

المؤلفون: Cutsem EV, Prenen H, Delafontaine B, Spencer K, Mitchell T, Burris H, Kotecki N, Kristeleit R, Pinato D, Sahebjam S, Graham D, Karasic T, Daniel J, O’Hayer K, Geschwindt R, Piha-Paul S

Relation: http://purl.org/net/epubs/work/52369720

الاتاحة: http://purl.org/net/epubs/work/52369720